Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
Phase 2
Completed
- Conditions
- Hepatitis B
- Registration Number
- NCT00051038
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie entecavir's efficacy in HIV/HBV co-infected patients on lamivudine?
How does entecavir combination therapy compare to standard lamivudine monotherapy in HIV/HBV co-infected patients with viremia?
Which biomarkers correlate with treatment response to entecavir in chronic hepatitis B patients co-infected with HIV?
What are the potential adverse events associated with entecavir-lamivudine combination therapy in HIV/HBV co-infection?
What are the current combination strategies involving nucleoside analogs for managing drug-resistant HBV in HIV co-infected populations?
Trial Locations
- Locations (1)
Local Institution
🇺🇸Pittsburgh, Pennsylvania, United States
Local Institution🇺🇸Pittsburgh, Pennsylvania, United States